immediate feedback

« Back

Alejandro Barbagelata, M.D.
Associate Professor, Division of Cardiology

Alejandro Barbagelata, M.D.

Alejandro Barbagelata, M.D.
Associate Director of Heart Failure, Assist Devices and Transplant
Director Heart Failure Fellowship Program
Associate Professor of Medicine
Division of Cardiology
Department of Internal Medicine

University of Texas Medical Branch
301 University Blvd.
5.106 John Sealy Annex
Galveston, TX 77555-0553
Phone: 409.772.9835

Clinical Expertise

  1. Heart Failure, Assist Devices, Transplant
  2. Invasive cardiology
  3. Cardiac Intensive Care

Research Interests

  1. Translational research in Acute and Chronic Heart Failure
  2. Newer invasive techniques such as percutaneous devices for circulatory assistance or
    remote monitoring
  3. Acute myocardial infarction. Electrocardiographic prognostic and management strategies


Dr. Barbagelata is an Argentinean native, obtained his MD degree in the Buenos Aires University in Argentina and finished his Medical Resident and Cardiology Fellowship training at the Favaloro Foundation/ Sanatorio Guemes in Buenos Aires; which was the largest cardiovascular institution in Latin America at that time, founded by Dr. Rene G Favaloro, worldwide known for having implemented the Coronary artery Bypass in 1967.

He was awarded as an International Scholar at the Cleveland clinic in 1990 in artificial heart and Cardiovascular Research Fellow at Duke Clinical Research Institute 1992-1994, where he was instrumental in implementing the first international experience with the Duke Cardiovascular Research Databank.

Dr. Barbagelata was Staff member of the Cardiovascular Department from 1993-1999 at the Favaloro Foundation. Invasive Cardiologist at the Italian Hospital and Co-director of Trials Argentina Group Organization in Buenos Aires from 2000-2004.

In 2005 he became Faculty in the Division of Cardiology at UTMB. In 2006 he became Associate Medical Director of the Heart Failure, Assist Devices and Transplantation and also serve as an invasive cardiologist in the Catheterization Laboratory and Coronary care and Step down Unit attending.

Dr. Barbagelata has authored or co-authored significant research contributions in the fields of Heart failure and Acute Myocardial Infarction published by the top journals such as Circulation, The Journal of the American College of Cardiology, Journal of the American Medical Association, American Heart Journal and The New England Journal of Medicine.


Degree Year Institution
B.A. 1976 Liceo militar general San Martin
M.D. 1982 University of Buenos Aires School of Medicine
Internal Medicine
Fundacion Favaloro/Sanatorio Güemes' Buenos Aires, Argentina
Cardiovascular Disease
Fundacion Favaloro/Sanatorio Güemes' Buenos Aires, Argentina

Select Publications

  1. Barbagelata A, Califf RM, Topol EJ, Ohman M, Kereiakes D, George B, Leimberger J, Mark D and the TAMI study group. Recurrent ischemia after thrombolytic therapy is a frequent, important and expensive adverse clinical outcome. Am J Cardiol 1995; 76:1007-1013
  2. Sgarbossa EB, Pinski SL, Barbagelata A, Underwood D, Yamanouchi Y, Topol EJ, Califf RM, Gates S, Wagner GS. Electrocardiographic diagnosis of impending acute myocardial infarction in the presence of left bundle branch block. N Eng J Med 1996; 334:481-7
  3. Barbagelata A, Sgarbossa EB, Califf RM, Wagner GS, Granger GB, Stebbins A, Gates K. Q wave MI vs non Q wave myocardial infarction after thrombolytic therapy. One year prognosis after hospital discharge. A GUSTO I substudy. J Am Coll Cardiol 1997; 29:771-777
  4. Mahaffey KW, Puma JA, Barbagelata NA, Casas C, Lambe L, Orlandi C, Califf RM, Granger CB. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo controlled trial. The Acute Myocardial Infarction Study of Adenosine (AMISTAD) Trial. J Am Coll Cardiol 1999; 34:1711-1720.
  5. Gheorghiade M, O'Connor C, Adams K, Gattis W, Barbagelata A, Elkayam U, McGrew F, Ghali J, Benza R, Klapholz M, Orlandi C, for the ACTIV Trial Investigators. Acute and Chronic Therapeutic Impact of a Vasopressin 2 Antagonist (Tolvaptan) in Congestive Heart Failure (ACTIV in CHF): A multicenter, randomized trial in patients hospitalized with worsening heart failure. JAMA 2004; 291:1963-71.
  6. Alejandro Barbagelata, MD, Marcelo Di Carli, MD, Robert M Califf, MD, Jyostna Garg , MS, Yochai Birnbaum, MD, Liliana grinfeld, MD, Raymond Gibbons, MD, Christopher Granger, MD, Shaum G. Goodman, MD, Galen S Wagner, MD. Electrocardiographic Infarct Size After Thrombolysis. Insights from the AMISTAD Trial. Am H Journal 2005. Am Heart J. 2005 Oct;150(4):659-65
  7. The new concept of interventional heart failure therapy--part 1: electrical therapy, treatment of CAD, fluid removal, and ventricular support. Thompson KA, Philip KJ, Barbagelata A, Schwarz ER. J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):102-11
  8. Transplant of High PRA LVAD Patients Without Crossmatch using on bypass Pheresis and Alemtuzumab. Lick Scott, Kislingbury K, Kollar A, Barbagelata A, Indrokovs A, Koerner M, Valentine V. The Annals Of Thoracic Surgery 2011.
  9. Hypothyroidism and renal Function in Patients with systolic Heart Failure. Merla R, Martinez M, Kaliphe W, Bionat S, Bionat J, Barbagelata A. Tx H Inst J 2010: 37 (1) :66-9
  10. Cardiac Allograft Vasculopathy : Advances in Diagnosis. Cai Q, Rangasetty U, Barbagelata A, Koerner M. Cardiology Rev. 2011, 19 (1): 30-5
Site Managed by UTMB Information Design Services.